Whole-Body Biodistribution and Radiation Dosimetry of 18F-GE067: A Radioligand for In Vivo Brain Amyloid Imaging
Whole-Body Biodistribution and Radiation Dosimetry of 18F-GE067: A Radioligand for In Vivo Brain Amyloid Imaging
复制标题
DOI：
10.2967/jnumed.108.060756
复制
发表时间：
2009-05-01
影响因子：
9.3
通讯作者：
Van Laere, Koen
中科院分区：
文献类型：
--
作者：
Koole, Michel;Lewis, Dewi M.;Van Laere, Koen
我们对F-18-3′-F-6-OH-BTA1 （F-18-GE067）的生物分布和剂量学进行了表征，F-18-GE067是一种新开发的用于可视化和量化淀粉样蛋白负荷的放射性配体。方法：6名受试者（男5名，女1名，年龄51-74岁）在注射F-18-GE067后6小时进行动态全身PET/CT检查。在PET/CT上圈定源器官。测定了个体器官剂量和有效剂量。结果：无不良事件发生，无明显临床变化。F-18-GE067主要通过肝胆系统排泄。胆囊、上大肠和小肠是吸收剂量最高的器官（平均分别为287、173和155 μ Gy/MBq）。平均有效剂量为33.8 +/- 3.4 μ Sv/MBq，与许多其他f -18标记的放射性药物的剂量相当。结论：F-18-GE067用于PET淀粉样蛋白成像的估计有效剂量是可以接受的（世界卫生组织定义的II-b级），受试者之间的差异相对较小。
We have characterized the biodistribution and dosimetry of F-18-3'-F-6-OH-BTA1 (F-18-GE067), a newly developed radioligand to visualize and quantify amyloid burden, in healthy elderly human subjects. Methods: Six subjects (5 men and 1 woman; age range, 51-74 y) underwent dynamic whole-body PET/CT for 6 h after a bolus injection of F-18-GE067. Source organs were delineated on PET/CT. Individual organ doses and effective doses were determined. Results: No adverse events or clinically significant changes were observed. F-18-GE067 is excreted predominantly through the hepatobiliary system. The gallbladder, upper large intestine, and small intestine are the organs with the highest absorbed dose (average, 287, 173, and 155 mu Gy/MBq, respectively). The mean effective dose was 33.8 +/- 3.4 mu Sv/MBq, a dose comparable to that of many other F-18-labeled radiopharmaceuticals. Conclusion: The estimated effective dose of F-18-GE067 for PET amyloid imaging was acceptable (class II-b defined by the World Health Organization), and relatively low variability between subjects was observed.